Key result
Calcium channel blockers were associated with higher mean serum creatinine and proteinuria compared to ACEIs or ARBs in nondiabetic CKD, with no difference in reaching Cr >7 mg/dL or dialysis.
Why the study?
Do regimens including calcium channel blockers (CCBs) prevent progression of kidney disease compared to ACEIs/ARBs in patients with nondiabetic chronic kidney disease?
Observational
Do regimens including calcium channel blockers (CCBs) prevent progression of kidney disease compared to ACEIs/ARBs in patients with nondiabetic chronic kidney disease?
Calcium channel blockers are less effective than ACE inhibitors or ARBs at preserving renal function and reducing proteinuria in patients with nondiabetic chronic kidney disease.
CCBs linked to higher creatinine and proteinuria than ACEIs/ARBs in nondiabetic CKD; leaves open effects on hard renal endpoints and should not yet change practice.
We aimed to compare regimens including calcium channel blockers (CCBs) to non-CCBs agents such as angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin receptor blockers (ARBs) regarding progression in nondiabetic chronic kidney disease (CKD). There was no difference in reaching serum creatinine concentration (Cr) to more than 7 mg/dL and/or commencing dialysis. The CCB group compared to non-CCBs displayed a higher mean Cr (as well as a higher rate of increase) and proteinuria. Medication with CCBs and younger age were associated with adverse renal function outcome. It is concluded that CCBs are less effective than ACEIs or ARBs on preserving renal function and ameliorating proteinuria in nondiabetic CKD.
No takes yet. Share an insight, caveat, or question.
Ziakka et al. (2007) conducted an observational in Nondiabetic chronic kidney disease (CKD). Calcium channel blockers (CCBs) vs. Non-CCB agents (ACEIs and/or ARBs) was evaluated on Reaching serum creatinine concentration > 7 mg/dL and/or commencing dialysis. Calcium channel blockers were associated with higher mean serum creatinine and proteinuria compared to ACEIs or ARBs in nondiabetic CKD, with no difference in reaching Cr >7 mg/dL or dialysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: